Inovio Pharmaceuticals Inc has described a new modality for generating monoclonal antibodies that involves the use of DNA plasmid technology to produce specific antibody molecules in the bloodstream of mice.
Trials of potential treatments for both early and late-onset Alzheimer’s diseases are among seven projects to receive $45 million in new funding from the National Institutes of Health as part of a US effort to accelerate research into the disease.
For the first time, researchers have identified the majority of mutational signatures associated with tumour development in 30 of the most common cancer types. The findings, published in Nature, are expected to inform future strategies for disease prevention and treatment.
Results from an animal study suggest that endothelial precursor cells could play a role in minimising initial brain injury from a stroke and help repair stroke damage, according to an article in the August issue of STEM CELLS Translational Medicine.
Scientists in the Netherlands have reported that the DNA in the nucleus of an embryonic stem cell appears to be folded in such a way that all stem cell genes are located near one another. This ensures that stem cells don’t change into other cell types.
Analysing data from a small population in northeastern Finland, an international research group has identified a genetic link to schizophrenia, as well as an association with the rare disease Fragile X syndrome. The findings were reported in Nature Neuroscience.
Researchers from Ireland have reported that the probiotic B. infantis 35624 relieved symptoms in three inflammatory disorders underscoring the role that the gut microbiota plays in human health. The study appears in the July/August issue of Gut Microbes.
The Belgian university, KU Leuven, has joined forces with a small company in Finland to develop new immunotherapies using a proprietary gene expression technology. The Finnish partner is FIT Biotech of Tampere.
The French specialty pharmaceutical company Ipsen SA has reached an agreement to acquire Syntaxin Ltd of the UK in a deal potentially valued at €158 million, while simultaneously announcing an agreement in neurology with Harvard Medical School.
Using an RNA viral vector, researchers from the University of California, San Francisco have created induced pluripotent stem cells (iPSC) from blood cells which they say can be easily differentiated into haematopoietic stem and progenitor cells.